As indicated in our study, the immunological TME in the brain, including the infiltration of PD-1+ TILs, may be important in predicting the clinical benefits of PD-1/PD-L1 checkpoint blockades in lung cancer patients with BM. Here, PDCD1 is linked to lung cancer.